SBFM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sunshine Biopharma Inc (SBFM) is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is trading pre-market at 2.36 and is already below the pivot level of 2.501, while the moving averages remain bearish (SMA_200 > SMA_20 > SMA_5). Although MACD is positive and expanding, the overall trend still looks weak, and the stock trend model points to downside over the next day and month. With no supportive news, no recent analyst upgrades, and no strong proprietary buy signal, the current setup does not justify an immediate buy.
SBFM's technical picture is mixed to bearish. The MACD histogram is positive at 0.0958 and expanding, which suggests short-term momentum is improving. However, RSI_6 at 33.635 is only near neutral and not a strong bullish signal. The moving averages are bearish, with SMA_200 above SMA_20 above SMA_5, confirming the broader trend is still weak. Pre-market price at 2.36 is below the pivot at 2.501, with support at 2.104 and resistance at 2.899. The modeled stock trend also indicates a 70% chance of a -1.76% move next day, which reinforces a weak near-term setup.
Hedge funds are buying aggressively, with buying amount up 11812.88% over the last quarter. MACD is improving and expanding above zero, which may indicate some short-term momentum recovery.
No news in the past week means there is no fresh event-driven catalyst. Insider trading is neutral with no significant activity. Bearish moving averages show the stock remains in a downtrend. The pre-market price is slightly negative at -0.42%, and the trend model suggests further downside over the short and medium term. No recent congress trading data is available, and there is no AI Stock Picker or SwingMax buy signal today.
No usable financial snapshot was provided because the financial data returned an error ('list index out of range'), so the latest quarter season and revenue or earnings growth trends cannot be assessed.
No analyst rating or price target change data was provided, so Wall Street sentiment appears unavailable. Based on the data given, there is no evidence of a strong pro-stock analyst consensus or rising price target trend.
